Collaborate with NCATS Scientists

Biomedical Data Translator

NCATS’ Biomedical Data Translator program aims to accelerate biomedical translation by developing a biomedical “data translator” for the research community. Through this program, NCATS will integrate multiple types of existing data sources and reveal potential relationships across the spectrum of data types. For more information, send an email to​.

Bridging Interventional Development Gaps (BrIDGs)

Through its BrIDGs program, NCATS assists researchers in advancing promising therapeutic agents through late-stage preclinical development toward an Investigational New Drug application and clinical testing. To discuss a potential collaboration with BrIDGs scientists, contact

Functional Genomics Lab

The Functional Genomics Lab, administered by staff in NCATS’ Division of Preclinical Innovation, is designed to help NIH investigators use the latest functional genomics technology to advance drug discovery and scientific knowledge about health and disease. To learn more, contact Ken Cheng, Ph.D.

Licensing, Technology Transfer & Patents

NCATS’ strategic alliances team helps industry and academic researchers interact and partner with Center laboratories and scientists. The Center’s support for technology development and partnership includes day-to-day negotiations of transactional agreements and licenses between NCATS and outside parties, including universities, pharmaceutical companies and biotechnology companies. For more information, email

NCATS Early Translation Branch (ETB)

NCATS’ ETB program staff offer biomedical researchers access to large-scale screening capacity and medicinal chemistry and informatics expertise to develop chemical probe molecules. These resources can help scientists study the functions of genes, cells and biochemical pathways. The program also features assay development and high-throughput screening, chemistry and chemistry technology, automation, and informatics. To learn more and to obtain ETB probe molecules, contact ETB.

Pfizer's Centers for Therapeutic Innovation (CTI) for NIH Researchers

NCATS is facilitating Pfizer's CTI program at NIH, which pairs NIH intramural researchers and clinicians with Pfizer resources to pursue scientific and medical advances through joint therapeutic development of biological compounds. For more information, contact

Stem Cell Translation Laboratory (SCTL)

Through the SCTL, NCATS provides researchers across various disciplines and organizations with the ability to establish collaborations to advance the translation of regenerative medicine applications. NCATS seeks stem cell research collaborators from the biotechnology, pharmaceutical, and NIH intramural and extramural communities on an ongoing basis. Proposal receipt dates are July 1, November 1 and March 1. To learn more, contact Carlos A. Tristan, Ph.D.

Therapeutics for Rare and Neglected Diseases (TRND)

The TRND program provides collaborators with access to significant in-kind resources and expertise in the preclinical and early clinical development of new therapeutics for rare conditions and neglected tropical diseases. To discuss a potential collaboration with TRND scientists, contact to learn more.

Toxicology in the 21st Century (Tox21)

The goal of the Tox21 program is to test 10,000 chemicals and evaluate their potential to cause health problems. Any investigator may propose the development of biological assays for high-throughput screening. Proposed assays must be compatible with the high-throughput screening guidelines described in the assay guidance criteria. To suggest an assay, submit a nomination form (PDF - 44KB) to Menghang Xia, Ph.D.

Collaborate on Other Intramural Projects

Connect with our intramural researchers to explore collaboration opportunities. To view existing project collaborations, visit the NIH Intramural Database and select “National Center for Advancing Translational Sciences (NCATS)” in the “Select Institute or Center” drop-down menu.